The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial

Gibson C. M., Halaby R., Korjian S., Daaboul Y., Arbetter D. F., Yee M. K., ...More

AMERICAN HEART JOURNAL, vol.185, pp.93-100, 2017 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 185
  • Publication Date: 2017
  • Doi Number: 10.1016/j.ahj.2016.12.004
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.93-100
  • Hacettepe University Affiliated: Yes


Background The APEX trial assessed the safety and efficacy of extended-duration thromboprophylaxis using betrixaban versus standard dosing of enoxaparin among hospitalized, acutely ill medical patients. The 80-mg betrixaban dose was halved to 40 mg among subjects with severe renal insufficiency and those receiving a concomitant strong P-glycoprotein inhibitor.